Neuren Pharmaceuticals Ltd has released a press release.
Acadia provides update on EU regulatory submission
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Response to ASX Aware Letter
- DAYBUE net sales projected to reach approx US$700m in 2028
- FDA approves DAYBUE STIX (trofinetide), powder formulation
- Record DAYBUE net sales of US$101.1 million in Q3 2025
- Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
Later from Neuren Pharmaceuticals
- Trading Halt
- Neuren receives US FDA meeting feeback for HIE and PTHS
- First patient dosed in Neuren PMS Phase 3 trial
- Neuren to commence new on-market share buy-back program
- Pause in Trading
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals